Tag Archives: ruxolitinib

October, 2018

January, 2017

February, 2016

  • 11 February

    Incyte Discontinues Late-Stage Study of its Pancreatic Cancer Combo

    WILMINGTON, Del.–(BUSINESS WIRE)–Feb. 11, 2016– Incyte Corporation (Nasdaq: INCY) announced today its decision to discontinue the Phase 3 study (JANUS 1) of ruxolitinib or placebo in combination with capecitabine for the second-line treatment of patients with advanced or metastatic pancreatic cancer. The decision to stop the study was made after …